NCT04980534View on ClinicalTrials.gov

Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

June 30, 2021

Study Completion Date

September 15, 2021

Conditions
Covid19COVID-19 PneumoniaCOVID-19 Respiratory InfectionViral InfectionRespiratory Tract InfectionsInfection, CoronavirusSARS-CoV2 Infection
Interventions
DIETARY_SUPPLEMENT

Viusid and Asbrip

Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.

DRUG

COVID-19 Standard Therapy

Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.

Trial Locations (3)

010000

City center for infectious diseases, Astana

"JSC Astana Medical University", Astana

020000

City children hospital №1, Astana

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT04980534 - Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip | Biotech Hunter | Biotech Hunter